The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 801–900 of 1,000
Nanomaterials-enabled mRNA delivery for Cancer immunotherapy
Chen, Y., Liang, S., Peng, Y., Ma, K., Yun, K., Ma, X., Hai, L., Mei, L., Wang, L., & Wang, Z. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216945 · Cited by 2
Kobayashi, D., Kosumi, T., Lam, Q. L. K., Fujita, S., Hijikata, Y., Takeda, K., Narita, T., Yamashita, N., Richard, G., Groot, A. S. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609116 · Cited by 2
Minimalist mRNAs: A fast track to cancer vaccines
Salaberry, L., Covo-Vergara, Á., Beloki, U., Silva-Pilipich, N., & Smerdou, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102669 · Cited by 2
Olsen, T. A., Barnum, K. J., Avigan, D., & Rosenblatt, J. M. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101650 · Cited by 2
Biosafety and regulatory issues of RNA therapeutics
Thị, H. V., Thi, L.-A. N., Tang, T. L., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.008 · Cited by 2
The Role of Therapeutic Vaccines in Cancer Immunotherapy
Baxevanis, C. N., Tsitsilonis, O., Goulielmaki, M., Tsakirakis, N., & Gritzapis, A. D. (2025) · Onco · doi:10.3390/onco5010011 · Cited by 2
Screening of Autophagy-Related Prognostic Genes in Metastatic Skin Melanoma
Chen, C.-J., Kajita, H., Aramaki‐Hattori, N., Sakai, S., & Kishi, K. (2022) · Disease Markers · doi:10.1155/2022/8556593 · Cited by 2
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021
Ascierto, P. A., Butterfield, L. H., Finn, O. J., Futreal, P. A., Hamid, O., LaVallee, T. M., Postow, M. A., Puzanov, I. J., Sosman, J. A., Fox, B. A., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03384-w · Cited by 2
Combinatorial Strategies for T Lymphocyte-Based Cancer Immunotherapy
Hargadon, K. M., & Wall, J. B. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_211-1 · Cited by 2
The potential of mRNA vaccine in HCC treatment
Han, R. (2023) · International Journal of Immunotherapy and Cancer Research · doi:10.17352/2455-8591.000037 · Cited by 2
Materials-Based Approaches for Cancer Vaccination
Sobral, M. C., & Mooney, D. J. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300482 · Cited by 2
Yekedüz, E., Ayasun, R., Köksoy, E. B., Utkan, G., Ürün, Y., & Akbulut, H. (2021) · Future Virology · doi:10.2217/fvl-2021-0166 · Cited by 2
An ex vivo human model for safety assessment of immunotoxicity of engineered nanomaterialsPreprint
Blersch, J., Kurkowsky, B., Meyer-Berhorn, A., Grabowska, A. K., Feidt, E., Junglas, E., Roth, W., Stappert, D., Kübelbeck, A., Denner, P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.29.547008 · Cited by 2
Adotévi, O. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.002 · Cited by 2
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy
Billmeier, A., Khinvasara, K., Lang, F., Mohr, J., Reidenbach, D., Schork, M., Yildiz, I., & Diken, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2024416 · Cited by 1
Self-citationMessenger RNA Lipid-Based Nanoparticles: Optimization of Formulations in the Lab
Delehedde, C., Ciganek, I., Laroui, N., Rameix, N., Perche, F., & Pichon, C. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_12 · Cited by 1
Self-assembling nanoparticles for miRNA delivery towards precision medicine against melanoma
Nele, V., Liguoro, D., Campani, V., Angelillo, A., Frigerio, R., Ortolano, A., Mancini, R., Fattore, L., Rosa, G. D., & Ciliberto, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106169 · Cited by 1
Qu, W., & Zhu, S. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101404 · Cited by 1
mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma
Feng, Y., Du, Y., Zhang, C.-T., Xie, F., & Yan, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189493 · Cited by 2
mRNA-based immunotherapy platform targeting endometrial cancer
Freyberg, M., Dierks, M., Naß, N., George, C., Geffken, M., Ignatov, A., Kalinski, T., & Ignatova, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07497-w · Cited by 2
Combinatorial Strategies for T Lymphocyte-Based Cancer Immunotherapy
Hargadon, K. M., & Wall, J. B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_211 · Cited by 1
Tuning the loading position of mRNA onto ionizable neo-liposomes to improve endosomal escape
Qin, Z., Qu, Y., Tian, W., Tao, P., Yang, L., Zhao, R., Ying, Q., Liu, H., Lu, Y., Jiang, Y., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100339 · Cited by 1
Karimi, H., Seifollahi, N., Yavari, P., Pourrostam, M., Nourbakhsh, S., Rahmati, S., & Rostaminasab, G. (2026) · Medical Oncology · doi:10.1007/s12032-026-03237-2 · Cited by 1
Bo, Y., Liu, B., Huang, S., Liu, Y., Deng, L., Zhang, D., & Zhang, J. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag047 · Cited by 1
Multiplexed spatial screening of lipid-based nanoparticles for extrahepatic messenger RNA targeting
Enzlein, T., Schumacher, J., Geisel, A., Keller, F., Houben, A., Walzer, K. C., Rittel, M. F., Fröhlich, B., Cairns, J. L., Cordes, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114728 · Cited by 2
Self-citationWang, Z., Zuo, S., Wan, X., He, Y., Jiang, X., Fan, G., Liu, Q., Shao, D., Liu, Q., & Zhang, Y. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102968 · Cited by 1
Liu, Y., Zhou, J., Gong, Z., Feng, Y., Li, X., Shang, Q., Wu, Y., & Yang, Y. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101612 · Cited by 1
Lin, X., Chen, G., Tang, R., Wu, M., Zhang, D., Lin, F., Guan, J., Yang, J., Dong, X., Zheng, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102754 · Cited by 1
Raheem, K. Y., Nawaz, M., Alzahrani, K. J., Ali, I., & Muddassar, M. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00631-6 · Cited by 1
Dodopoulos, A., Syrianou, N., & Stamatopoulos, P. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108445 · Cited by 1
Jiang, Y., Luo, J., Liu, C., Xue, W., liu, J., Wang, M., Shi, S., Yin, X., & li, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114992 · Cited by 1
Efficacy and Safety of Messenger RNA Vaccines
Batisani, K., & Chisompola, D. (2026) · Health Science Reports · doi:10.1002/hsr2.72595 · Cited by 1
Singh, B., Sah, A., Ghosh, B., & Kumar, D. (2026) · Nano LIFE · doi:10.1142/s1793984426300141 · Cited by 1
Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives
Vatankhah, A., Moghaddam, S. H., Rahmanian, M., Khosropanah, S., Oroojalian, F., Kesharwani, P., & Sahebkar, A. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02728-0 · Cited by 1
Vaccination-enabled immune readiness for checkpoint blockade
Bautista, J., & López-Cortés, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1790344 · Cited by 1
Therapeutic cancer vaccines: development, challenges, and future perspectives
Di, D., Li, L.-F., He, T.-Y., Cui, H.-X., Nian, Y., Jiao, X., Han, C.-Y., & Wei, M. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01928-0 · Cited by 1
Ferrantelli, F., Manfredi, F., Donnini, M., Leone, P., Pugliese, K., Olivetta, E., Giovannelli, A., Virgilio, A. D., Federico, M., & Chiozzini, C. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00831-2 · Cited by 1
A comprehensive review of anticancer drug therapy: Advances and challenges
Mohammed, S. A., Kadhim, A. J., & Hussein, M. S. (2025) · International Journal of Pharmaceutical and Clinical Research · doi:10.33545/26647591.2025.v7.i1a.115 · Cited by 1
Cancer Vaccines: A Promising Therapeutic Strategy in Advanced Solid Tumors
Caridi, S., Maccauro, V., Cerrito, L., Ianiro, G., Pallozzi, M., Stella, L., Gasbarrini, A., & Ponziani, F. R. (2025) · Vaccines · doi:10.3390/vaccines13060591 · Cited by 1
Jung, D., Cai, X., Wan, Z., Khalil, E. A., Lee, N., Ramseier, N. T., Bao, Q., Zhao, Z., Hu, Y. C., Lim, S., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115053 · Cited by 1
King, E., Saha, C., Saleem, R., Jiang, B., O’Donoghue, E., Cottone, F., McCarthy, H. O., & Piskareva, O. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201244 · Cited by 1
Yadava, S. K., Tripathi, A., Kabilan, M., Champion, J. A., & Cicerone, M. T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114312 · Cited by 1
Recent advancements in cancer vaccine developments: novel approaches
Ejeta, B. M., Das, M. K., Das, S., Bakare, F. F., Ayana, O. T., & Jamatia, T. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2621220 · Cited by 1
Pedersen, G. K., Alhakeem, R. S., Tami, A., Christensen, D., Shabanian, Z., Jensen, R. F., Wørzner, K., & Schmidt, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04234-3 · Cited by 1
Aparicio, B., Silva, L., Ruiz, M., Llópiz, D., Repáraz, D., Theunissen, P., Tamayo, I., Egea, J., Igea, A., Smerdou, C., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2645280 · Cited by 1
mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules
Kakroudi, M. H., Rezvanimehr, A., Zolfaghari, K., Baghaei-Shiva, G., Abbasi, H., Pourashory, M., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2026) · Discover Oncology · doi:10.1007/s12672-026-04811-w · Cited by 1
Zhou, Y., Fang, J., Fei, L., Li, H., Xu, X., Xie, J., & Qi, M. (2026) · Human Mutation · doi:10.1155/humu/9909803 · Cited by 1
Cudog, C. J. A., Arcilla, T. A. A., Gregorio, A. M. D., Ramos, S. D., Salazar, E. S., Sindingan, J. L., Tubalinal, M. J. L., Huang, H.-Y., Wu, P.-H., Minh, H., et al. (2026) · J — Multidisciplinary Scientific Journal · doi:10.3390/j9020015 · Cited by 1
Therapeutic Cancer Vaccines: Mechanisms, Clinical Progress, and Future Directions
Wilson, K., Banda, J. F., Bukkapatnam, S., Raza, F., & Massarelli, E. (2026) · Vaccines · doi:10.3390/vaccines14070599 · Cited by 1
Frei, J., Eisel, D., Jarzębska, N. T., Mellett, M., Yener, I. G., Abdou, M. T., Gouttefangeas, C., Flatz, L., Diken, M., Kündig, T. M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01738-z · Cited by 1
Self-citationZeng, Y., Xu, J., Wang, J., Xue, L., Liu, J., Geisler, H. C., Xu, M., Melamed, J. R., Shi, Q., Padilla, M. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525718123 · Cited by 1
Meisel, A., & Pascolo, S. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.045 · Cited by 2
RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy
Deng, Y., Xiao, M., Wan, A. H., Li, J., Sun, L., Liang, H., Wang, Q., Yin, S., Bu, X., & Wan, G. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0035 · Cited by 1
Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure
Konig, S., Strobel, H., Grunert, M., Łyszkiewicz, M., Brühl, O., Karpel‐Massler, G., Ziętara, N., Ferla-Brühl, K. L., Siegelin, M. D., Debatin, K., et al. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2114454 · Cited by 1
Xie, B., Zhang, L., Gao, J., Wang, T.-E., Liu, M., Feng, X., Xu, X., Ma, S., Cai, H., Guo, T., et al. (2023) · PubMed Central · Cited by 1
Schäfer‐Korting, M. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_696 · Cited by 1
Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter
Zeyn, Y., Hobernik, D., Wilk, U., Pöhmerer, J., Hieber, C., Medina‐Montano, C., Röhrig, N., Strähle, C. F., Thoma‐Kress, A. K., Wagner, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316938 · Cited by 1
Engineered polymer‐based scaffold as an implantable therapeutic vaccine against melanoma
Unnikrishnan, A., Menon, M., Gopika, K. G., Sam, R. E., Koyakutty, M., & Ashokan, A. (2023) · Journal of Applied Polymer Science · doi:10.1002/app.55032 · Cited by 1
New approaches to vaccines for cancer
Chavda, V. P., Acharya, D., Malla, S., Ashby, C. R., & Tiwari, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00009-6 · Cited by 1
Nanoencapsulation approaches for enhancing cancer therapy
Chura, S. S. D., Sudo, K. A., Faria, J. A. Q. A., Borges, G. S. M., & Carneiro, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00020-8 · Cited by 1
RNAs in the diagnosis and treatment of major diseases
Huang, D., Zhang, T., Jiang, X., Li, J., Yan, Z., Sun, R., Su, S., & Hong, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0523 · Cited by 1
Pioneering Immunotherapy Agents and Their Synergy with Radiotherapy
Zhang, S.-J., Zheng, L., Cao, L., Wang, G.-R., Xiao, Y., Wu, Q., Liu, B., & Bu, L. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_9 · Cited by 1
A new frontier in oncology: Understanding the landscape of cancer vaccines
Suvvari, T. K., Killi, K., Veggalam, S., & Kandi, V. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251375363 · Cited by 1
mRNA Structuring for Stabilizing mRNA Nanocarriers and Improving Their Delivery Efficiency
Uchida, S., Koji, K., Yoshinaga, N., Mochida, Y., Hong, T., & Cabral, H. (2020) · International Online Conference on Nanomaterials (IOCN) · doi:10.3390/iocn2020-07789 · Cited by 1
Fehse, B. (2021) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783748927242-156 · Cited by 1
Nanomaterials as Novel Biomarkers for Cancer Nanotheranostics: State of the Art
Yu, H., Han, Z., Chen, C., & Zhang, L. (2022) · Biomedical engineering · doi:10.5772/intechopen.105700 · Cited by 1
Ushakova, E. I., Fedorova, A. A., Лебедева, Е. С., Av, P., & Ataullakhanov, R. I. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-4-389-400 · Cited by 1
Ushakova, E. I., Av, P., Fedorova, A. A., Лебедева, Е. С., & Ataullakhanov, R. I. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-6-691-701 · Cited by 1
Mélanome métastatique, immunothérapie et survie à long terme : où en sommes-nous ?
Robert, C. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.020 · Cited by 1
Nanoparticle‐Based mRNA Vaccines
Nalla, L. V., Gajula, S. N. R., & Chavda, V. P. (2024) · Wiley eBooks · doi:10.1002/9781394175482.ch8 · Cited by 1
Thrift, W. J., Broadwell, Q., Perera, J. F., Lounsbury, N., Chen, J., & Jhunjhunwala, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618255 · Cited by 1
Karmakar, S., & Lal, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.26.640476 · Cited by 1
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9109248/v1 · Cited by 1
Vaccination influenz(a)ing cancer‐specific survival
Wolf, D. G. F., & Pircher, A. (2020) · International Journal of Cancer · doi:10.1002/ijc.33341
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020
Ascierto, P. A., Brody, J., Butterfield, L. H., Finn, O. J., Goldberg, J., Perrone, F., Sullivan, R. J., Fox, B. A., Hwu, P., & Puzanov, I. J. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02811-8
Tumorvakzinierung –Strategien und Timing
Maringer, Y., & Walz, J. S. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00532-4
Therapeutic cancer vaccines: reasons to believe
Moore, J. D. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210205
The RNA World: The Best of Times, the Worst of Times
VandenDriessche, T. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29173.tvd
Fawaz, B., Sahni, D., & Lerner, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_15
Roerden, M., & Walz, J. S. (2021) · best practice onkologie · doi:10.1007/s11654-021-00356-2
Quoi de neuf en dermato-oncologie ?
Aubin, F. (2021) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(21)01529-4
Potential Positive Effects of COVID-19 on Cancer Care: A Window of Opportunity
Damilakis, E. (2022) · International Journal of Public Health · doi:10.3389/ijph.2022.1604394
Conforti, A., Palombo, F., & Aurisicchio, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00002-9
Himuro, H., & Sasada, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00007-8
Identification of tumor antigens for T-cell-mediated cancer immunotherapy
Rammensee, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00010-8
Tumor immunology and the application of immunotherapy in ovarian carcinoma
Paijens, S. T. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182133606
Roerden, M., & Walz, J. S. (2021) · Der Onkologe · doi:10.1007/s00761-021-01012-8
Materials at the heart of the COVID-19 pandemic
(2022) · Nature Materials · doi:10.1038/s41563-022-01289-z
Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges
Zhang, L., & Cai, H. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105184
Bhojak, K., Kode, V., Miriam, C. M., Lee, K. M., Ramesh, A., Sudheendra, H., Chakraborty, P., & Chaudhuri, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.11.499638
Cheng, H., & Tai, H. (2022) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.4
Potential in anti-cancer therapy using RNA - overview of therapies
Rusinowska, B. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.07.082
Novel Therapies in Clinical Development for Advanced Disease
Arraez, Á. S., Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107089
Rakké, Y. S., Welters, M. J. P., Noordam, L., Boekestijn, S., Magré, L., Luijten, R. J., van Gemerden, R. S., de Beijer, M. T. A., Doukas, M., Demmers, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1181
Messenger RNA Nanovaccine in Cancer Immunotherapy
Li, M., & Zhang, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_9
Vakzinierungsstrategien beim Mammakarzinom
Schmidt, M. (2022) · Die Gynäkologie · doi:10.1007/s00129-022-05027-z
Personalized Cancer Vaccines Targeting Neoantigens
Himuro, H., & Sasada, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_291-1
Immunotherapy-based Combination Therapies for Malignant Melanomas
Sharif, P. M., & Rezaei, N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_29
Natural Killer Cells - Lessons and Challenges
Zhang, L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.105658
Natural Killer Cells for Cancer Immunotherapy: Opportunities and Challenges
Zhang, L., Feng, X., Han, Z., & Han, Z. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109480
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
